BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28452187)

  • 1. N-acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: A meta-analysis.
    Feng Y; Huang X; Li L; Chen Z
    Nephrology (Carlton); 2018 Jun; 23(6):530-538. PubMed ID: 28452187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis.
    Subramaniam RM; Suarez-Cuervo C; Wilson RF; Turban S; Zhang A; Sherrod C; Aboagye J; Eng J; Choi MJ; Hutfless S; Bass EB
    Ann Intern Med; 2016 Mar; 164(6):406-16. PubMed ID: 26830221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
    Briguori C; Airoldi F; D'Andrea D; Bonizzoni E; Morici N; Focaccio A; Michev I; Montorfano M; Carlino M; Cosgrave J; Ricciardelli B; Colombo A
    Circulation; 2007 Mar; 115(10):1211-7. PubMed ID: 17309916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
    Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
    Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
    Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
    J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.
    Kang X; Hu DY; Li CB; Ai ZS; Peng A
    Ren Fail; 2015 Nov; 37(10):297-303. PubMed ID: 26458505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of the impact of N-acetylcysteine on contrast nephropathy.
    Pannu N; Manns B; Lee H; Tonelli M
    Kidney Int; 2004 Apr; 65(4):1366-74. PubMed ID: 15086476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials.
    Sun Z; Fu Q; Cao L; Jin W; Cheng L; Li Z
    PLoS One; 2013; 8(1):e55124. PubMed ID: 23383076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of N--acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis.
    O'Sullivan S; Healy DA; Moloney MC; Grace PA; Walsh SR
    Angiology; 2013 Nov; 64(8):576-82. PubMed ID: 23188834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Zagler A; Azadpour M; Mercado C; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
    Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
    J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of short-term infusion regimens of N-acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department.
    Kama A; Yılmaz S; Yaka E; Dervişoğlu E; Doğan NÖ; Erimşah E; Pekdemir M
    Acad Emerg Med; 2014 Jun; 21(6):615-22. PubMed ID: 25039544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhao SJ; Zhong ZS; Qi GX; Tian W
    Int J Cardiol; 2016 Oct; 221():251-9. PubMed ID: 27404685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascorbic Acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial.
    Dvoršak B; Kanič V; Ekart R; Bevc S; Hojs R
    Ther Apher Dial; 2013 Aug; 17(4):384-90. PubMed ID: 23931876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials.
    Ma WQ; Zhao Y; Wang Y; Han XQ; Zhu Y; Liu NF
    Int Urol Nephrol; 2018 Jun; 50(6):1085-1095. PubMed ID: 29404930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.
    Chousterman BG; Bouadma L; Moutereau S; Loric S; Alvarez-Gonzalez A; Mekontso-Dessap A; Laissy JP; Rahmouni A; Katsahian S; Brochard L; Schortgen F
    J Crit Care; 2013 Oct; 28(5):701-9. PubMed ID: 23683568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.